Jim Miller

The PharmTech/PharmSource annual outsourcing survey results suggest that CDMOs may be getting complacent.

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Eisai and Biogen Idec pursue an innovative approach to capacity management.

Eisai and Biogen Idec pursue an innovative approach to capacity management.

Is the contract-only CMO an endangered species?

Is the contract-only CMO an endangered species?

Preferred-provider relationships are transforming the bio/pharmaceutical industry.

The quest to build critical mass and broaden capabilities has been a key factor in dealmaking.

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Annual survey shows strong growth for service providers and promises to continue into 2013.

Service providers must focus on delivering a superior customer experience.

Service providers must focus on delivering a superior customer experience.

The evolving bio/pharmaceutical business model poses risk for CMOs.

The evolving bio/pharmaceutical business model poses risk for CMOs.

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Respondents to the 2011 PharmSource-Pharmaceutical Technology Outsourcing Survey paint a positive picture, but concerns linger under the surface. This article is part of a special issue on Outsourcing.

Lessons from the earthquake in Japan show the vulnerability of the bio/pharma supply chain.